Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome
The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every...
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
SAGE Publishing
2014-11-01
|
| سلاسل: | Therapeutic Advances in Neurological Disorders |
| الوصول للمادة أونلاين: | https://doi.org/10.1177/1756285614549554 |